Literature DB >> 8634695

Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene.

V M Steen1, A Molven, N K Aarskog, A K Gulbrandsen.   

Abstract

The cytochrome P450 enzyme debrisoquine 4-hydroxylase (CYP2D6) metabolizes many different classes of commonly used drugs. In Caucasian populations, 5-10% are classified as poor metabolizers (PM) due to autosomal recessive inheritance of two mutant CYP2D6 null alleles. In contrast, up to 5% may demonstrate ultrarapid metabolism (UM) of debrisoquine caused by inherited amplification of functional CYP2D6 genes in the CYP2D6 locus. Poor metabolizer subjects may develop toxic plasma concentrations and adverse drug reactions, whereas UMs may suffer from therapeutic failure. Moreover, mutant CYP2D6 alleles have been implicated as a predictor of susceptibility for diseases such as cancer and neurological disorders. The break points and molecular mechanisms involved in the generation in the PM-associated CYP2D6(D) gene deletion allele and the UM-related CYP2D6 amplification have not been clarified. Here we demonstrate the presence of a 2.8 kb repeated region (CYP-REP) which flanks the active CYP2D6 gene in the wild type allele. The CYP-REP unit may be itself predispose to homologous unequal cross-over and contains the Alu element and a tandem 10 bp direct repeat, which could both serve as hotspots for recombination. The break points of the CYP2D6(D) deletion allele are present within the repeated 2.8 kb region, but the exact positions are non-determinable due to perfect recombination of the misaligned, homologous CYP-REP elements. We also propose that the alleles with multiple copies of CYP2D6, which represent the first example of inherited amplification of an active gene in man, can be explained by unequal cross-over events involving the CYP-REP units. In our model, the CYP2D6 deletion and amplification alleles are reciprocal to each other, generated through homologous unequal recombination of no-allelic CYP-REP elements.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8634695     DOI: 10.1093/hmg/4.12.2251

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  17 in total

1.  Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction.

Authors:  John Logan Black; Denise L Walker; Dennis J O'Kane; Maria Harmandayan
Journal:  Drug Metab Dispos       Date:  2011-10-17       Impact factor: 3.922

2.  Genome-wide analysis of recombination machinery for spliceosomal introns gain.

Authors:  Haidong Tan
Journal:  Mol Biol Rep       Date:  2009-05-17       Impact factor: 2.316

3.  Hybrid survival motor neuron genes in patients with autosomal recessive spinal muscular atrophy: new insights into molecular mechanisms responsible for the disease.

Authors:  E Hahnen; J Schönling; S Rudnik-Schöneborn; K Zerres; B Wirth
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

Review 4.  Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

Authors:  T Yokoi; T Kamataki
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

5.  Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.

Authors:  Jennifer Lee; Selina Moy; John Meijer; Walter Krauwinkel; Taiji Sawamoto; Virginie Kerbusch; Donna Kowalski; Michael Roy; Alan Marion; Shin Takusagawa; Marcel van Gelderen; James Keirns
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

6.  CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction.

Authors:  Andrea Gaedigk; Uwe Fuhr; Charlene Johnson; L Anick Bérard; Dianne Bradford; J Steven Leeder
Journal:  Pharmacogenomics       Date:  2010-01       Impact factor: 2.533

Review 7.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.

Authors:  Ulrich M Zanger; Sebastian Raimundo; Michel Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-15       Impact factor: 3.000

9.  CYP2D6: novel genomic structures and alleles.

Authors:  Whitney E Kramer; Denise L Walker; Dennis J O'Kane; David A Mrazek; Pamela K Fisher; Brian A Dukek; Jamie K Bruflat; John L Black
Journal:  Pharmacogenet Genomics       Date:  2009-10       Impact factor: 2.089

10.  Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors.

Authors: 
Journal:  Genet Med       Date:  2007-12       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.